This study, as well as those demonstrating the different effects of FcγR allele variants on therapeutic responses and prognosis in MS and other immune-mediated diseases (29–32), suggest that the effects of increased IgG3 proportions in serum on the immune cells that express FcγRs warrant further investigation in MS. Here, IGHG3 is linked to myeloid sarcoma.